These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 17664471)

  • 1. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
    Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
    J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
    Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
    Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
    Huang F; Xu LA; Khambata-Ford S
    Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
    Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
    Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
    Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
    Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
    BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
    Lièvre A; Laurent-Puig P
    Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
    Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
    Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
    Strimpakos A; Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Andreadou A; Sgouros J; Zizi-Sermpetzoglou A; Kominea A; Televantou D; Razis E; Galani E; Pectasides D; Tejpar S; Syrigos K; Fountzilas G
    Clin Colorectal Cancer; 2013 Dec; 12(4):267-274.e2. PubMed ID: 24050852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].
    Levi Y; Barshack I; Avivi K; Bar-ILan D; Gutman M; Aderka D; Berger R; Yacobi R
    Harefuah; 2013 Jun; 152(6):326-9, 369. PubMed ID: 23885463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
    Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
    Jonker DJ; Karapetis CS; Harbison C; O'Callaghan CJ; Tu D; Simes RJ; Malone DP; Langer C; Tebbutt N; Price TJ; Shapiro J; Siu LL; Wong RP; Bjarnason G; Moore MJ; Zalcberg JR; Khambata-Ford S
    Br J Cancer; 2014 Feb; 110(3):648-55. PubMed ID: 24335920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
    Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
    Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
    J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.
    Jing C; Jin YH; You Z; Qiong Q; Jun Z
    Oncotarget; 2016 Aug; 7(34):55890-55899. PubMed ID: 27344184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.